Jones Day (Washington)

Michael H. Knight

Jones Day (Washington)
Partner

Mike Knight is partner at Jones Day (Washington). He advises clients on all aspects of competition law, including mergers, joint ventures, competitor collaborations, distribution issues, price discrimination, monopolization, and intellectual property restraints. He has experience in government and the private sector and routinely represents clients before federal and state antitrust agencies and federal courts. From 2003 to 2007, Mike served as an assistant director of the Federal Trade Commission’s Bureau of Competition, where he headed the Bureau’s Mergers II Division, overseeing hundreds of investigations, including the Blockbuster/Hollywood, Sony/BMG, and Brocade/McData transactions. He was a trial attorney at the U.S. Department of Justice Antitrust Division from 1997 to 2000. In private practice before joining Jones Day, Mike represented technology firms Adobe, NVIDIA, and Synopsys, among other clients. Mike currently serves as a vice chair of the American Bar Association Section of Antitrust Law’s Joint Conduct Committee. He writes and speaks frequently on antitrust enforcement topics.

Distinctions

Linked authors

Jones Day (Sydney)
Jones Day (Mexico)
Jones Day (Brussels)
Jones Day (New York)
Jones Day (Madrid)

Articles

6192 Bulletin

Antonio F. Dias, David M. Morrell, Louis K. Fisher, Lin W. Kahn, Michael H. Knight The US Supreme Court blocks the FTC from obtaining monetary remedies in most antitrust and consumer protection cases (AMG Capital Management)

212

The Supreme Court ruled unanimously in AMG Capital Management v. FTC that Federal Trade Commission Act ("FTCA") Section 13(b) does not authorize the FTC to obtain monetary remedies such as restitution or disgorgement. The Court’s decision is a significant setback for the FTC, particularly in (...)

Michael A. Gleason, Michael H. Knight, Peter J. Love, Pamela L. Taylor, Ryan C. Thomas The US FTC and the US DoJ announce the suspension of the discretionary practice of granting early termination of the waiting period to filings made under the Hart-Scott-Rodino Act

26

On February 4, 2021, the U.S. antitrust agencies announced that they are temporarily suspending the discretionary practice of granting early termination of the waiting period to filings made under the Hart-Scott-Rodino ("HSR") Act. Since January 16, the agencies granted ET in just one (...)

Michael A. Gleason, Michael H. Knight, Lauren Miller Forbes, John W. Magruder The US DoJ and FTC issue guidance on merger review during the COVID-19 outbreak and confirm that they continue to operate despite merging parties expecting lengthier reviews

149

The FTC and DOJ have adopted new procedures in response to the novel coronavirus (COVID-19) pandemic. The changes are intended to help the agencies stay open during the crisis, but merging parties should expect lengthier antitrust reviews until normal operations resume. All merger filings with (...)

Pamela L. Taylor, Peter J. Love, Michael H. Knight The US FTC announces its adjustments to the HSR Act threshold and determines which mergers and acquisitions must be reported to the federal government before consummation

105

This week, the Federal Trade Commission announced its 2020 adjustments to the Hart-Scott-Rodino ("HSR") Act thresholds. These thresholds determine which mergers and acquisitions must be reported to the federal government before consummation. The new thresholds take effect on February 27, and (...)

Michael H. Knight, Geoffrey D. Oliver, Larissa C. Bergin The US Court of Appeals for the Third Circuit limits the FTC’s ability to seek damages for past conduct in a pharmaceutical patent abuse case (Shire Viropharma)

24

In Short The Situation: The United States Court of Appeals for the Third Circuit ruled that the FTC could not recover past profits under FTC Act Section 13(b) if the alleged violation occurred in the past and the defendant was not "violating" or "about to violate" the law. The Impact: The (...)

Kathryn Fenton, Michael H. Knight, Bruce McDonald, Ryan C. Thomas, Thomas D. York The US District Court for the District of Columbia rejects the DoJ’s challenge to a vertical merger between an entertainment company and a distribution company (AT&T / Time Warner)

298

This article has been nominated for the 2019 Antitrust Writing Awards. Click here to learn more about the Antitrust Writing Awards. Court Rejects DOJ Antitrust Challenge to AT&T/Time Warner* After eighteen months of investigation and litigation, a federal district court has rejected the (...)

Bruce McDonald, Harris Nathaniel J., Kathryn Fenton, Michael H. Knight, Ryan C. Thomas, Thomas D. York The US FTC publishes a blog post reminding merging parties to avoid creating antitrust liability through the exchange of competitively sensitive information during merger negotiations

451

In Short The Situation: The Federal Trade Commission ("FTC") recently published a blog post reminding merging parties to avoid creating antitrust liability through the exchange of competitively sensitive information during merger negotiations and due diligence. The Risk: Information-sharing (...)

David P. Wales, Kathryn Fenton, Michael H. Knight, Paula W. Render, Thomas D. York The Federal Trade Commission revises the Merger rules which implements automatic atay of Administrative litigation when Agency loses preliminary injunction in Court

116

This article has been nominated for the 2016 Antitrust Writing Awards. Click here to learn more about the Antitrust Writing Awards. One important procedural difference between merger challenges by the U.S. Department of Justice and the Federal Trade Commission is that FTC may challenge a (...)

Michael H. Knight, Michael Sennett, Philip A. Proger The US FTC releases a summary of its new report on pharma patent litigation finding an increase in reverse payment settlements based on an expanded definition of payments

747

With the Supreme Court set to address the validity of "reverse payment" settlements of pharmaceutical patent litigation, the FTC released a summary of its new report, announcing that in 2012 drug companies entered "a record number" of such settlements. However, the underlying data and analysis (...)

David P. Wales, Geoffrey D. Oliver, Michael H. Knight The US FTC sues to undo completed acquisition in the healthcare industry approved by the Bankruptcy Court (LabCorp / Westcliff)

595

The Federal Trade Commission has filed an administrative lawsuit seeking to undo Laboratory Corporation of America’s (« LabCorp ») acquisition of Westcliff Medical Laboratories, Inc. (« Westcliff »). According to the agency’s December 1 complaint, the merger will substantially lessen competition (...)

Geoffrey D. Oliver, Michael H. Knight, Toby G. Singer The US District Court for the District of Minnesota dismisses the US FTC complaint seeking divestiture and disgorgement remedy in consummated acquisition in the healthcare industry (Lundbeck)

1343

In a decision that was filed under seal in late August but released publicly just last week, the U.S. District Court for the District of Minnesota dismissed with prejudice the complaint filed by the Federal Trade Commission (FTC) and the State of Minnesota challenging the already-consummated (...)

Send a message